TECTONIC THERAPEUTIC, INC. Research and Development Expense
TECTONIC THERAPEUTIC, INC. (TECX) reported Research and Development Expense of $18.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- TECTONIC THERAPEUTIC, INC. research and development expense for the quarter ending 2026-06-30 was $18.05M, a 5.02% increase year-over-year.
- TECTONIC THERAPEUTIC, INC. research and development expense for the quarter ending 2026-03-31 was $20.87M, a 60.10% increase year-over-year.
- TECTONIC THERAPEUTIC, INC. research and development expense for the quarter ending 2025-12-31 was $16.34M, a 78.47% increase year-over-year.
- TECTONIC THERAPEUTIC, INC. research and development expense for the quarter ending 2025-09-30 was $16.93M, a 18.23% increase year-over-year.
- TECTONIC THERAPEUTIC, INC. research and development expense for fiscal 2025 was $63.49M, a 53.49% increase from fiscal 2024.
- TECTONIC THERAPEUTIC, INC. research and development expense for fiscal 2024 was $41.36M, a 11.90% increase from fiscal 2023.
- TECTONIC THERAPEUTIC, INC. research and development expense for fiscal 2023 was $36.97M, a 48.79% decline from fiscal 2022.
- TECTONIC THERAPEUTIC, INC. research and development expense for fiscal 2022 was $72.19M, a 13.15% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $18.05M 10-Q · filed 2026-08-06 | $38.92M 10-Q · filed 2026-08-06 | $55.26M derived: sum of 3 quarters · filed 2026-08-06 | $72.19M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $20.87M 10-Q · filed 2026-05-07 | $37.21M derived: sum of 2 quarters · filed 2026-05-07 | $54.14M derived: sum of 3 quarters · filed 2026-05-07 | $71.32M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $16.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $33.27M derived: sum of 2 quarters · filed 2026-02-26 | $50.45M derived: sum of 3 quarters · filed 2026-08-06 | $63.49M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $16.93M 10-Q · filed 2025-11-06 | $34.11M derived: sum of 2 quarters · filed 2026-08-06 | $47.15M 10-Q · filed 2025-11-06 | $56.30M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $17.18M 10-Q · filed 2026-08-06 | $30.22M 10-Q · filed 2026-08-06 | $39.38M derived: sum of 3 quarters · filed 2026-08-06 | $53.69M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $13.04M 10-Q · filed 2026-05-07 | $22.19M derived: sum of 2 quarters · filed 2026-05-07 | $36.51M derived: sum of 3 quarters · filed 2026-05-07 | $43.58M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $9.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $23.47M derived: sum of 2 quarters · filed 2026-02-26 | $30.55M derived: sum of 3 quarters · filed 2026-02-26 | $41.36M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $14.32M 10-Q · filed 2025-11-06 | $21.39M derived: sum of 2 quarters · filed 2025-11-06 | $32.21M 10-Q · filed 2025-11-06 | $39.40M derived: sum of 4 quarters · filed 2025-11-06 | ||||
| 2024-06-30 | $7.07M 10-Q · filed 2025-08-07 | $17.89M 10-Q · filed 2025-08-07 | $25.08M derived: sum of 3 quarters · filed 2025-08-07 | $33.22M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $10.82M 10-Q · filed 2025-05-08 | $683.00K 10-Q · filed 2024-05-09 | $18.01M derived: sum of 2 quarters · filed 2025-05-08 | $26.14M derived: sum of 3 quarters · filed 2025-05-08 | $34.91M derived: sum of 4 quarters · filed 2025-05-08 | |||
| 2023-12-31 | $7.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $15.33M derived: sum of 2 quarters · filed 2025-03-20 | $24.09M derived: sum of 3 quarters · filed 2025-03-20 | $36.97M 10-K · filed 2025-03-20 | $47.70M 10-K · filed 2024-03-14 | |||
| 2023-09-30 | $8.13M 10-Q · filed 2024-11-12 | $14.83M 10-Q · filed 2023-11-09 | $16.90M derived: sum of 2 quarters · filed 2024-11-12 | $29.77M 10-Q · filed 2024-11-12 | $43.31M 10-Q · filed 2023-11-09 | $52.37M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $8.77M 10-Q · filed 2024-08-14 | $11.15M 10-Q · filed 2023-08-10 | $21.75M 10-Q · filed 2024-08-14 | $28.48M 10-Q · filed 2023-08-10 | $44.24M derived: sum of 3 quarters · filed 2024-08-14 | $60.16M derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2023-03-31 | $17.33M 10-Q · filed 2024-05-09 | $35.47M derived: sum of 2 quarters · filed 2024-05-09 | $51.39M derived: sum of 3 quarters · filed 2024-05-09 | $70.27M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $18.14M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $34.06M derived: sum of 2 quarters · filed 2024-03-14 | $52.93M derived: sum of 3 quarters · filed 2024-03-14 | $72.19M 10-K · filed 2024-03-14 | ||||
| 2022-09-30 | $15.92M 10-Q · filed 2023-11-09 | $34.80M derived: sum of 2 quarters · filed 2023-11-09 | $54.05M 10-Q · filed 2023-11-09 | $73.05M derived: sum of 4 quarters · filed 2023-11-09 | ||||
| 2022-06-30 | $18.88M 10-Q · filed 2023-08-10 | $38.13M 10-Q · filed 2023-08-10 | $57.13M derived: sum of 3 quarters · filed 2023-08-10 | $80.17M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $19.25M 10-Q · filed 2023-05-11 | $38.25M derived: sum of 2 quarters · filed 2023-05-11 | $61.30M derived: sum of 3 quarters · filed 2023-05-11 | $83.84M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $19.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $42.04M derived: sum of 2 quarters · filed 2023-03-23 | $64.59M derived: sum of 3 quarters · filed 2023-03-23 | $83.11M 10-K · filed 2023-03-23 | ||||
| 2021-09-30 | $23.04M 10-Q · filed 2022-11-08 | $45.59M derived: sum of 2 quarters · filed 2022-11-08 | $64.11M 10-Q · filed 2022-11-08 | $83.70M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | $22.54M 10-Q · filed 2022-08-09 | $41.02M 10-Q · filed 2022-08-09 | $60.66M derived: sum of 3 quarters · filed 2022-08-09 | $89.17M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | $18.53M 10-Q · filed 2022-05-10 | $38.11M derived: sum of 2 quarters · filed 2022-05-10 | $66.62M derived: sum of 3 quarters · filed 2022-05-10 | $87.49M derived: sum of 4 quarters · filed 2022-05-10 | ||||
| 2020-12-31 | $19.59M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $48.10M derived: sum of 2 quarters · filed 2022-03-17 | $68.96M derived: sum of 3 quarters · filed 2022-03-17 | $87.24M 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | $28.51M 10-Q · filed 2021-11-04 | $49.38M derived: sum of 2 quarters · filed 2021-11-04 | $67.65M 10-Q · filed 2021-11-04 | $84.87M derived: sum of 4 quarters · filed 2021-11-04 | ||||
| 2020-06-30 | $20.87M 10-Q · filed 2021-08-05 | $39.14M 10-Q · filed 2021-08-05 | $56.36M derived: sum of 3 quarters · filed 2021-08-05 | $69.40M derived: sum of 4 quarters · filed 2021-08-05 | ||||
| 2020-03-31 | $18.27M 10-Q · filed 2021-05-13 | $35.49M derived: sum of 2 quarters · filed 2021-05-13 | $48.53M derived: sum of 3 quarters · filed 2021-05-13 | $60.80M derived: sum of 4 quarters · filed 2021-05-13 | ||||
| 2019-12-31 | $17.22M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $30.26M derived: sum of 2 quarters · filed 2021-03-18 | $42.53M derived: sum of 3 quarters · filed 2021-03-18 | $54.97M 10-K · filed 2021-03-18 | ||||
| 2019-09-30 | $13.04M 10-Q · filed 2020-11-05 | $25.31M derived: sum of 2 quarters · filed 2020-11-05 | $37.76M 10-Q · filed 2020-11-05 | $50.56M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | $12.27M 10-Q · filed 2020-08-06 | $24.71M 10-Q · filed 2020-08-06 | $37.52M derived: sum of 3 quarters · filed 2020-08-06 | $46.75M derived: sum of 4 quarters · filed 2020-08-06 | ||||
| 2019-03-31 | $12.45M 10-Q · filed 2020-05-07 | $25.25M derived: sum of 2 quarters · filed 2020-05-07 | $34.49M derived: sum of 3 quarters · filed 2020-05-07 | $41.89M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | $12.81M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $22.04M derived: sum of 2 quarters · filed 2020-03-16 | $29.45M derived: sum of 3 quarters · filed 2020-03-16 | $35.09M 10-K · filed 2020-03-16 | ||||
| 2018-09-30 | $9.23M 10-Q · filed 2019-11-07 | $16.64M derived: sum of 2 quarters · filed 2019-08-08 | $22.29M 10-Q · filed 2019-11-07 | $28.75M derived: sum of 4 quarters · filed 2019-08-08 | ||||
| 2018-06-30 | $7.41M 10-Q · filed 2019-08-08 | $13.05M 10-Q · filed 2019-08-08 | $19.52M derived: sum of 3 quarters · filed 2019-08-08 | $24.93M derived: sum of 4 quarters · filed 2019-08-08 | ||||
| 2018-03-31 | $5.65M 10-Q · filed 2019-05-13 | $12.11M derived: sum of 2 quarters · filed 2019-05-13 | $17.52M derived: sum of 3 quarters · filed 2019-05-13 | $19.40M derived: sum of 4 quarters · filed 2019-05-13 | ||||
| 2017-12-31 | $6.46M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-25 | $11.88M derived: sum of 2 quarters · filed 2019-03-25 | $13.76M derived: sum of 3 quarters · filed 2019-03-25 | $15.19M 10-K · filed 2019-03-25 | ||||
| 2017-09-30 | $5.41M 10-Q · filed 2018-11-13 | $7.29M derived: sum of 2 quarters · filed 2018-11-13 | $8.73M 10-Q · filed 2018-11-13 | |||||
| 2017-06-30 | $1.88M 10-Q · filed 2018-08-09 | $3.31M 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |